Macrocyclic inhibitors of flaviviridae viruses

Provided are compounds of Formula I and pharmaceutically acceptable salts and esters thereof, wherein A1 is (C2-C5)alkylene, (C2-C5)alkynylene, -O-(C2-C4)alkylene, -O-(C2 C4)alkenylene, arylene, aryl(C1-C2)alkylene, heterocycloalkylene, pyrazolylene, pyridylene or heterocycloalkyl(C1 C2)alkylene, wh...

Full description

Saved in:
Bibliographic Details
Main Authors Schrier, Adam James, Highton, Adrian John, Aciro, Caroline, Steadman, Victoria Alexandra, Dunbar, Neil Andrew, Mackman, Richard, Poullennec, Karine G, Lazarides, Linos, Karki, Kapil Kumar, Jansa, Petr, Keats, Andrew John, Pettit, Simon Neil, Dean, David Kenneth, Siegel, Dustin Scott
Format Patent
LanguageEnglish
Published 29.06.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided are compounds of Formula I and pharmaceutically acceptable salts and esters thereof, wherein A1 is (C2-C5)alkylene, (C2-C5)alkynylene, -O-(C2-C4)alkylene, -O-(C2 C4)alkenylene, arylene, aryl(C1-C2)alkylene, heterocycloalkylene, pyrazolylene, pyridylene or heterocycloalkyl(C1 C2)alkylene, wherein a sp3 carbon atom of A1 is optionally substituted with one or more (C1-C4)alkyl; A2 is arylene or heteroarylene, wherein A2 is optionally substituted with halo. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
Bibliography:Application Number: NZ20130724616